

Data Sharing Statement

Chari A, Vogl DT, Gavriatopoulou M, et al. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma. *N Engl J Med*. DOI: 10.1056/NEJMoa1903455.

Question	Authors' Response
Will the data collected for your study be made available to others?	Yes
Would you like to offer context for your decision?	—
Which data?	Other (eg, partial data sets) — please describe
Additional information about data	Karyopharm Therapeutics agrees to share individual participant data that underlie the results reported in this article (after deidentification), including the study protocol and statistical analysis plan.
How or where can the data be obtained?	To gain access, data requestors should submit a proposal to medicalinformation@karyopharm.com .
When will data availability begin?	9 months post publication
When will data availability end?	36 months post publication
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	To gain access, data requestors should submit a proposal to medicalinformation@karyopharm.com . Proposals will be reviewed by an independent review committee (“learned intermediary”) identified for this purpose.
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on August 22, 2019, at [NEJM.org](https://www.nejm.org).